Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2006 Jul;62(1):97-112.
doi: 10.1111/j.1365-2125.2006.02719.x.

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

N Widmer  1 , L A Decosterd, C Csajka, S Leyvraz, M A Duchosal, A Rosselet, B Rochat, C B Eap, H Henry, J Biollaz, T Buclin
Affiliations

Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein

N Widmer et al. Br J Clin Pharmacol. 2006 Jul.

Erratum in

  • Br J Clin Pharmacol. 2010 Aug;70(2):316

Abstract

Aims: The aims of this observational study were to assess the variability in imatinib pharmacokinetics and to explore the relationship between its disposition and various biological covariates, especially plasma alpha1-acid glycoprotein concentrations.

Methods: A population pharmacokinetic analysis was performed using NONMEM based on 321 plasma samples from 59 patients with either chronic myeloid leukaemia or gastrointestinal stromal tumours. The influence of covariates on oral clearance and volume of distribution was examined. Furthermore, the in vivo intracellular pharmacokinetics of imatinib was explored in five patients.

Results: A one-compartment model with first-order absorption appropriately described the data, giving a mean (+/-SEM) oral clearance of 14.3 l h-1 (+/-1.0) and a volume of distribution of 347 l (+/-62). Oral clearance was influenced by body weight, age, sex and disease diagnosis. A large proportion of the interindividual variability (36% of clearance and 63% of volume of distribution) remained unexplained by these demographic covariates. Plasma alpha1-acid glycoprotein concentrations had a marked influence on total imatinib concentrations. Moreover, we observed an intra/extracellular ratio of 8, suggesting substantial uptake of the drug into the target cells.

Conclusion: Because of the high pharmacokinetic variability of imatinib and the reported relationships between its plasma concentration and efficacy and toxicity, the usefulness of therapeutic drug monitoring as an aid to optimizing therapy should be further investigated. Ideally, such an approach should take account of either circulating alpha1-acid glycoprotein concentrations or free imatinib concentrations.

PubMed Disclaimer

Figures

Figure 4
Figure 4
Representation of the distribution of imatinib, based on concentrations and volumes (Vtot = Vd = total imatinib volume of distribution, VAGP = total α1-acid glycoprotein (AGP) plasma volume; Vu = free imatinib volume, Ctot = total imatinib concentration, Cu = free imatinib concentration, Cb = concentration of imatinib bound to AGP, AGPtot = total AGP concentration, AGPu = free AGP concentration, AGPb = concentration of AGP bound to imatinib, L = scaling factor)
Figure 2
Figure 2
Pharmacokinetic parameters derived from the demographic covariates model (left panel) and from the final α1-acid glycoprotein (AGP) model (right panel), plotted according to AGP plasma concentrations
Figure 1
Figure 1
Plasma imatinib concentrations observed in patients receiving imatinib, together with the mean population prediction (solid line) and 90% prediction interval (dashed lines). The graphs represent a once (upper part) or twice (lower part) daily regimen, based either on the demographic covariates model (left) or on the final α1-acid glycoprotein (AGP) model (right) (values adjusted to 400 mg q.d.; AGP model curves generated assuming mean values of AGP level and fu)
Figure 3
Figure 3
Intracellular and plasma pharmacokinetic profiles of imatinib in five individual patients (solid lines, plasma concentrations; broken lines, peripheral blood mononuclear cell concentrations)
See this image and copyright information in PMC

References

    1. Druker BJ. Imatinib mesylate in the treatment of chronic myeloid leukaemia. Expert Opin Pharmacother. 2003;4:963–71. - PubMed
    1. Tothova E, Kafkova A, Fricova M, Benova B, Kirschnerova G, Tothova A. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha. Neoplasma. 2005;52:63–7. - PubMed
    1. Steinert DM, McAuliffe JC, Trent JC. Imatinib mesylate in the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother. 2005;6:105–13. - PubMed
    1. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1:493–502. - PubMed
    1. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80. - PubMed

MeSH terms